<div id="readability-page-1">Ipswich Investment Management Co. Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 21.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,995 shares of the company's stock after acquiring an additional 1,230 shares during the quarter. Eli Lilly and Company makes up 1.2% of Ipswich Investment Management Co. Inc.'s holdings, making the stock its 24th biggest holding. Ipswich Investment Management Co. Inc.'s holdings in Eli Lilly and Company were worth $5,337,000 as of its most recent filing with the Securities and Exchange Commission (SEC).<ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul>Several other institutional investors have also added to or reduced their stakes in LLY. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company's stock valued at $62,680,004,000 after purchasing an additional 1,183,038 shares during the last quarter. Laurel Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock valued at $9,005,392,000 after buying an additional 11,537,661 shares during the period. Norges Bank bought a new stake in Eli Lilly and Company during the second quarter valued at $8,827,714,000. Jennison Associates LLC grew its holdings in Eli Lilly and Company by 4.3% during the 2nd quarter. Jennison Associates LLC now owns 5,447,636 shares of the company's stock worth $4,246,596,000 after acquiring an additional 226,620 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in Eli Lilly and Company by 7.9% during the 1st quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company's stock worth $4,496,187,000 after acquiring an additional 397,696 shares during the period. 82.53% of the stock is currently owned by institutional investors. <div>Get Eli Lilly and Company alerts:</div><h2>Wall Street Analyst Weigh In</h2>A number of brokerages have recently issued reports on LLY. Guggenheim reissued a &#34;buy&#34; rating and issued a $1,163.00 price objective on shares of Eli Lilly and Company in a research note on Wednesday, December 3rd. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a research note on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 price objective on shares of Eli Lilly and Company and gave the stock a &#34;buy&#34; rating in a research report on Tuesday. Morgan Stanley lifted their price objective on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an &#34;overweight&#34; rating in a research note on Monday, November 24th. Finally, Bank of America dropped their target price on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $1,141.73.<ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul>Check Out Our Latest Stock Report on LLY<h2>Eli Lilly and Company Price Performance</h2>Shares of NYSE:LLY opened at $1,071.35 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,111.99. The stock's 50 day moving average is $960.76 and its 200-day moving average is $830.36. The firm has a market capitalization of $1.01 trillion, a price-to-earnings ratio of 52.41, a PEG ratio of 1.33 and a beta of 0.37. <ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company's revenue was up 53.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year. <h2>Eli Lilly and Company Increases Dividend</h2>The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company's payout ratio is presently 29.35%. <h2>Eli Lilly and Company News Summary</h2>Here are the key news stories impacting Eli Lilly and Company this week:<ul> <li>Positive Sentiment: Late‑stage trial win — Lilly’s oral GLP‑1 pill orforglipron met the primary and all key secondary endpoints in the ATTAIN‑MAINTAIN Phase 3 trial, showing patients who switched from Wegovy or Zepbound kept essentially all prior weight loss; Lilly has submitted orforglipron to the FDA for obesity. PR Newswire: Lilly's orforglipron helped people maintain weight loss</li> <li>Positive Sentiment: Program momentum and regulatory progress — Chugai and other releases highlight positive topline Phase 3 results and Lilly’s FDA filing for orforglipron, reinforcing the company’s leadership in oral GLP‑1s. This raises prospects for rapid commercial adoption if approved. TipRanks: Chugai highlights positive Phase 3 results</li> <li>Positive Sentiment: Analyst upgrades and upside forecasts — Bank of America and other outlets point to improved quality metrics and forecast material upside (BofA cites potential multi‑billion sales for new oral obesity therapies), while Daiwa upgraded LLY — all supportive of higher valuations. Benzinga: BofA sees room for stock upside American Banking News: Daiwa upgrade</li> <li>Neutral Sentiment: Pipeline depth — Lilly advanced eloralintide into Phase 3, strengthening its obesity/diabetes pipeline beyond orforglipron; this is strategic for longer‑term growth but not an immediate revenue driver. TipRanks: Lilly advances eloralintide into Phase 3</li> <li>Neutral Sentiment: Branding/marketing initiatives — Lilly’s consumer outreach (e.g., Olympics tie‑ins) supports awareness for new therapies but has unclear near‑term financial impact. MM&amp;M: Lilly debuts video featuring Team USA</li> <li>Negative Sentiment: Pricing pressure in Canada — Reuters reported Lilly cut prices of Mounjaro and Zepbound in Canada by ~20% or more, which could compress margins or reduce realized revenue per prescription in markets facing tougher pricing/regulatory scrutiny. Reuters: Lilly cuts price of diabetes, weight-loss drugs in Canada</li> </ul><h2>About Eli Lilly and Company</h2> (Free Report)Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.<h2>Featured Stories</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>How Investors Can Find the Best Cheap Dividend Stocks</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>3 Healthcare Dividend Stocks to Buy</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>Asset Allocation Strategies in Volatile Markets</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul>Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).<img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>Before you consider Eli Lilly and Company, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

Ipswich Investment Management Co. Inc. increased its stake in Eli Lilly and Company by 21.3% in the third quarter, owning 6,995 shares valued at $5.34 million. This makes Eli Lilly 1.2% of Ipswich's holdings. Other institutional investors, like Vanguard and Norges Bank, also adjusted their stakes. Eli Lilly's stock has a consensus 'Moderate Buy' rating with an average target price of $1,141.73. The company reported strong quarterly earnings, with revenue up 53.9% year-over-year.

Ipswich Investment Management Co. Inc. Has $5.34 Million Stock Holdings in Eli Lilly and Company $LLY